CVL-006 / Convalife - LARVOL DELTA

An Open-label, Multicenter Phase I Clinical Study of CVL006, A novel PD-L1/VEGF Bispecific Antibody in Advanced Solid Tumors (ESMO 2026) - No abstract available

Bispecific • Clinical • Metastases • P1 data • Oncology • Solid Tumor

CVL006-T1003: Clinical Study of CVL006 Combination With 9MW2821 (clinicaltrials.gov) - P1/2 | N=108 | Not yet recruiting | Sponsor: Convalife (Shanghai) Co., Ltd.

New P1/2 trial • Head and Neck Cancer • Oncology • Parotid Gland Cancer • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • NECTIN4

Phase I/II clinical trial of CVL006 combination therapy in advanced solid tumors (AACR 2026) - P1/2 | "In this phase I/II Clinical Study of CVL006 combo with pemetrexed and carboplatin, or SKB264, or DS8201, or Enfortumab Vedotin, Safety, pharmacokinetics (PK) and preliminary efficacy will be assessed in adult subjects with advanced solid tumors, and, thus, the recommended phase II dose (RP2D) will be established (NCT07157956). This is a multicenter, open-label, phase I/II dose-escalation and dose-optimization clinical study. CVL006 combo with pemetrexed and carboplatin, or SKB264 appeared to be well tolerated and had encouraging preliminary efficacy in patients with advanced solid tumors, warranting further investigation."

Clinical • Combination therapy • Metastases • P1/2 data • Oncology • Solid Tumor • PD-L1

An open-label, multicenter Phase I clinical study of CVL006, a novel PD-L1/VEGF bispecific antibody, in advanced solid tumors (AACR 2026) - P1 | "CVL006 monotherapy appeared to be well tolerated and had encouraging preliminary efficacy in patients with advanced solid tumors, warranting further investigation."

Bispecific • Clinical • Metastases • P1 data • Oncology • Solid Tumor • PD-L1

Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2) (clinicaltrials.gov) - P1/2 | N=600 | Not yet recruiting | Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

IO biomarker • New P1/2 trial • Oncology • Solid Tumor

Preclinical evaluation of an anti-PD-L1/VEGF-A bispecific antibody CVL006 and its therapeutic potentials in combo with ADCs (ESMO 2025) - "The efficacy of CVL006 was parallelly compared to bevacizumab, atezolizumab and ivonescimab. Legal entity responsible for the study Convalife Pharmaceuticals Co., Ltd. Funding Convalife Pharmaceuticals Co., Ltd."

Preclinical • Colon Cancer • Colorectal Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor

A phase I study of CVL006, an anti-PD-L1/VEGF bispecific antibody, in advanced solid tumors (ESMO 2025) - P1 | "Legal entity responsible for the study Convalife Pharmaceuticals. Funding Convalife Pharmaceuticals."

Metastases • P1 data • Biliary Cancer • Cholangiocarcinoma • Colorectal Cancer • Gastric Cancer • Lung Cancer • Oncology • Solid Tumor • Submandibular Gland Cancer

CVL006-T1002: CVL006 Combination Therapy in Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=318 | Not yet recruiting | Sponsor: Convalife (Shanghai) Co., Ltd.

IO biomarker • New P1/2 trial • Lung Cancer • Non Small Cell Lung Cancer • Solid Tumor • Urothelial Cancer • PD-L1

A novel bispecific antibody CVL006 superior to AK112 for dual targeting of PD-L1 and VEGF in cancer therapy. (PubMed, Antib Ther) - "CVL006 integrates immune checkpoint inhibition and tumor vascularization disruption, offering a comprehensive anticancer strategy. Its superior preclinical performance compared to atezolizumab and AK112 underscores its therapeutic potential, paving the way for further development and clinical translation."

Journal • Oncology